Sunshine Biopharma, Inc. – NASDAQ:SBFM
Sunshine Biopharma stock price today
Sunshine Biopharma stock price monthly change
Sunshine Biopharma stock price quarterly change
Sunshine Biopharma stock price yearly change
Sunshine Biopharma key metrics
Market Cap | 5.43M |
Enterprise value | N/A |
P/E | -0.38 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 31.66 |
Price/Book | 0.30 |
PEG ratio | N/A |
EPS | -13.33 |
Revenue | 26.73M |
EBITDA | -3.44M |
Income | -4.08M |
Revenue Q/Q | 54.08% |
Revenue Y/Y | 193.29% |
Profit margin | -661.72% |
Oper. margin | -1010.45% |
Gross margin | 32.51% |
EBIT margin | -1010.45% |
EBITDA margin | -12.9% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSunshine Biopharma stock price history
Sunshine Biopharma stock forecast
Sunshine Biopharma financial statements
| Jun 2023 | 5.56M | -902.10K | -16.22% |
|---|---|---|---|
| Sep 2023 | 5.95M | -651.48K | -10.94% |
| Dec 2023 | 7.68M | -1.25M | -16.28% |
| Mar 2024 | 7.54M | -1.28M | -17.02% |
| 2025 | 100M | 145.99K | 0.15% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 28410022 | 5.30M | 18.66% |
|---|---|---|---|
| Sep 2023 | 27650284 | 5.68M | 20.57% |
| Dec 2023 | 27346961 | 6.13M | 22.45% |
| Mar 2024 | 31898717 | 7.07M | 22.19% |
| Jun 2023 | -3.77M | -259.47K | 4.05M |
|---|---|---|---|
| Sep 2023 | -457.28K | 18.85K | -63.56K |
| Dec 2023 | -2.68M | -269.23K | -30.51K |
| Mar 2024 | -3.18M | -668.73K | 5.39M |
Sunshine Biopharma alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 46 |
| Oct 2023 | 46 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 44 |
| Jun 2024 | 44 |
| Jul 2024 | 44 |
Sunshine Biopharma other data
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SLILATY STEVE N. director, 10 perc.. | Series B Preferred Stock | 20,000 | $0.1 | $2,000 | ||
Purchase | SEBAALY CAMILLE officer: CFO/Secr.. | Common Stock | 60,000 | $0.76 | $45,840 | ||
Purchase | SEBAALY CAMILLE officer: CFO/Secr.. | Common Stock | 25,000 | $1.22 | $30,500 | ||
Purchase | SLILATY STEVE N. director, officer.. | Common Stock | 253,082 | $0.2 | $50,110 | ||
Purchase | SLILATY STEVE N. director, 10 perc.. | Series "B" Preferred Stock | 500,000 | $0.1 | $50,000 | ||
Sale | SLILATY STEVE N. director, 10 perc.. | Common Stock | 2,591,500 | $0.05 | $129,575 |
-
What's the price of Sunshine Biopharma stock today?
One share of Sunshine Biopharma stock can currently be purchased for approximately $1.43.
-
When is Sunshine Biopharma's next earnings date?
Unfortunately, Sunshine Biopharma's (SBFM) next earnings date is currently unknown.
-
Does Sunshine Biopharma pay dividends?
No, Sunshine Biopharma does not pay dividends.
-
How much money does Sunshine Biopharma make?
Sunshine Biopharma has a market capitalization of 5.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 454.42% to 24.09M US dollars.
-
What is Sunshine Biopharma's stock symbol?
Sunshine Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "SBFM".
-
What is Sunshine Biopharma's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Sunshine Biopharma?
Shares of Sunshine Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sunshine Biopharma's key executives?
Sunshine Biopharma's management team includes the following people:
- Dr. Steve N. Slilaty Ph.D. Chairman, Chief Executive Officer & Pres(age: 73, pay: $177,000)
- Dr. Abderrazzak Merzouki Chief Operating Officer & Director(age: 61, pay: $24,930)
- Mr. Camille Sebaaly Chief Financial Officer & Sec.(age: 66, pay: $20,000)
-
How many employees does Sunshine Biopharma have?
As Jul 2024, Sunshine Biopharma employs 44 workers, which is 4% less then previous quarter.
-
When Sunshine Biopharma went public?
Sunshine Biopharma, Inc. is publicly traded company for more then 3 years since IPO on 15 Feb 2022.
-
What is Sunshine Biopharma's official website?
The official website for Sunshine Biopharma is sunshinebiopharma.com.
-
Where are Sunshine Biopharma's headquarters?
Sunshine Biopharma is headquartered at 6500 Trans-Canada Highway, Pointe-Claire, QC.
-
How can i contact Sunshine Biopharma?
Sunshine Biopharma's mailing address is 6500 Trans-Canada Highway, Pointe-Claire, QC and company can be reached via phone at +51 44 266161.
Sunshine Biopharma company profile:
Sunshine Biopharma, Inc.
sunshinebiopharma.comNASDAQ
44
Drug Manufacturers - Specialty & Generic
Healthcare
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Pointe-Claire, QC H9R 0A5
CIK: 0001402328
ISIN: US8677814035
CUSIP: 867781304
